独家专报！蔚来秦力洪呼吁行业携手共建换电体系：电池寿命问题迫在眉睫

蔚来秦力洪呼吁行业携手共建换电体系：电池寿命问题迫在眉睫

北京 - 在近日举办的第十六届中国汽车蓝皮书论坛上，蔚来汽车联合创始人、总裁秦力洪发表演讲，呼吁包括华为在内的更多车企加入换电阵营，共同应对汽车电池寿命带来的挑战。

秦力洪指出，随着电动汽车保有量的快速增长，电池寿命问题已经成为行业亟待解决的难题。从2025年起，预计将有约2000万辆电动汽车动力电池陆续脱离质保期，如果按照平均8万元每块电池的更换成本计算，总额将高达1.6万亿元。这笔巨大的开支不仅会给车主带来沉重的经济负担，也可能对环境造成二次污染。

他强调，换电模式可以有效解决电池寿命问题，为用户提供更加便捷、经济、环保的用车体验。蔚来已经率先在换电领域取得了成功，目前累计建成换电站超1000座，服务超20万用户。

秦力洪特别呼吁华为加入换电阵营，发挥其在技术和产业链方面的优势，助力换电体系的快速普及。他表示，蔚来愿意与华为开放合作，共同打造面向未来的电动汽车能源生态。

业内人士普遍认为，秦力洪的呼吁具有重要意义。随着新能源汽车产业的快速发展，电池寿命问题将日益凸显，换电模式有望成为未来主流的电动汽车补能方式。华为作为全球领先的技术企业，如果能够加入换电阵营，将无疑会对行业发展产生重大推动作用。

以下是新闻稿的几点补充：

• 除了电池寿命问题之外，秦力洪还谈到了其他一些影响电动汽车普及的关键因素，包括充电速度、续航里程、电池成本等。他呼吁行业共同努力，加快电动汽车相关技术的研发和应用，推动产业升级。
• 华为尚未对秦力洪的呼吁作出回应。不过，华为此前曾表示对换电模式持开放态度，并正在积极布局相关业务。
• 换电模式与充电模式相比，具有明显的优势，但也存在一些不足，例如换电站建设成本高、对电池标准化要求高等。未来，如何进一步完善换电模式，使其更具经济性和通用性，将是行业需要重点研究的课题。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.